micronized progesterone 400 mg (Utrogestan)
Drugparticipants receive vaginal micronized progesterone (Utrogestan- 200mg×2 PV(per vagina) per day)
Other names: Utrogestan- 200mg×2 PV(per vagina) per day
NCT Number: NCT02430233
Patients diagnosed with arrested pre-term labor following tocolytics at 24-34 gestational weeks will be randomly allocated to receive either vaginal micronized progesterone 400 mg/day or no treatment.
Looking for future studies?
Notify Me18 year and older
Female
Interventional
Phase 4
Poriya Medical Center, Tiberias, North, Israel
Since progesterone derivatives are useful in preventing preterm labor in cases of risk factors or previous preterm labor, we hypothesize that they will also show efficacy in pregnancy prolongation in women whose preterm labor was arrested following tocolytic treatment.
Patients diagnosed with arrested pre-term labor following tocolytics at 24-34 gestational weeks will be randomly allocated to receive either vaginal micronized progesterone 400 mg/day or no treatment.
This study has the potential to find a treatment to prevent preterm labor and thus to reduce neonatal morbidity and mortality.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
participants receive vaginal micronized progesterone (Utrogestan- 200mg×2 PV(per vagina) per day)
Other names: Utrogestan- 200mg×2 PV(per vagina) per day
Time frame: Up to 18 weeks
Time frame: Up to 13 weeks
defined as spontaneous labor or preterm delivery following induction/cesarean section due to preterm premature rupture of membranes prior to 37 weeks of gestation
Time frame: Up to 13 weeks
Time frame: Up to 18 weeks
Time frame: Up to 13 weeks
Time frame: Up to 13 weeks
Time frame: Up to 13 weeks
Time frame: From delivery and up to 28 days
Time frame: From delivery and up to 3 months
Time frame: From delivery and up to 3 months
Time frame: Around delivery
Time frame: Around delivery
Time frame: From delivery and up to 3 months
including transient tachypnea, RDS (respiratory distress syndrome), bronchopulmonary dysplasia, ventilatory support, supplemental oxygen, IVH (intraventricular hemorrhage), NEC (necrotizing enterocolitis), PDA (patent ductus arteriosus), retinopathy, neonatal sepsis, and congenital abnormalities not previously identified (specifically genital abnormalities).
Time frame: around delivery and up to 1 week post-partum
Time frame: Up to 13 weeks
Time frame: From delivery and up to 1 week post-partum
Time frame: During the 48 hours from delivery
Time frame: Up to 13 weeks
HaEmek Medical Center, Israel
Other
Vaginal Progesterone for the Prolongation of Pregnancy After Arrested Pre-term Labor - Randomized Double Blind Placebo Controlled Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07336173
Female Urogenital Diseases and Pregnancy Complications, Obstetric Labor Complications
Kafr ash Shaykh, Egypt
View Trial DetailsNCT07695467
Female Urogenital Diseases and Pregnancy Complications, Obstetric Labor Complications
Sivas, Kayseri Ave, Turkey (Türkiye)
View Trial DetailsNCT07649668
Female Urogenital Diseases and Pregnancy Complications, Obstetric Labor Complications
Faisalabad, Punjab Province, Pakistan
View Trial DetailsNCT04417595
Chemically-Induced Disorders, Female Urogenital Diseases and Pregnancy Complications
Nashville, Tennessee, United States
View Trial Details